Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.
Saved in:
| Title: | Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. |
|---|---|
| Authors: | Burston HE; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Kent OA; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Communal L; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.; Institut du Cancer de Montréal, Montréal, Quebec, Canada., Udaskin ML; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Sun RX; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Brown KR; Banting and Best Department of Medical Research, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada., Jung E; Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Francis KE; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., La Rose J; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Lowitz J; Antibody Solutions, Santa Clara, California, USA., Drapkin R; Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Mes-Masson AM; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.; Institut du Cancer de Montréal, Montréal, Quebec, Canada.; Département de Médecine, Université de Montréal, Montreal, Quebec, Canada., Rottapel R; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.; Department of Medical Biophysics, Department of Immunology, University of Toronto, Toronto, Ontario, Canada.; Division of Rheumatology, St. Michael's Hospital, Toronto, Ontario, Canada. |
| Source: | The Journal of clinical investigation [J Clin Invest] 2021 Apr 01; Vol. 131 (7). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33561012 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Burston+HE%22">Burston HE</searchLink>; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Kent+OA%22">Kent OA</searchLink>; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Communal+L%22">Communal L</searchLink>; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.; Institut du Cancer de Montréal, Montréal, Quebec, Canada.<br /><searchLink fieldCode="AU" term="%22Udaskin+ML%22">Udaskin ML</searchLink>; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Sun+RX%22">Sun RX</searchLink>; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Brown+KR%22">Brown KR</searchLink>; Banting and Best Department of Medical Research, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Jung+E%22">Jung E</searchLink>; Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Francis+KE%22">Francis KE</searchLink>; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22La+Rose+J%22">La Rose J</searchLink>; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Lowitz+J%22">Lowitz J</searchLink>; Antibody Solutions, Santa Clara, California, USA.<br /><searchLink fieldCode="AU" term="%22Drapkin+R%22">Drapkin R</searchLink>; Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Mes-Masson+AM%22">Mes-Masson AM</searchLink>; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.; Institut du Cancer de Montréal, Montréal, Quebec, Canada.; Département de Médecine, Université de Montréal, Montreal, Quebec, Canada.<br /><searchLink fieldCode="AU" term="%22Rottapel+R%22">Rottapel R</searchLink>; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.; Department of Medical Biophysics, Department of Immunology, University of Toronto, Toronto, Ontario, Canada.; Division of Rheumatology, St. Michael's Hospital, Toronto, Ontario, Canada. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227802877%22">The Journal of clinical investigation</searchLink> [J Clin Invest] 2021 Apr 01; Vol. 131 (7). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Clinical+Investigation%22">American Society for Clinical Investigation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7802877 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1558-8238 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200219738%22">00219738 </searchLink><i>NLM ISO Abbreviation: </i>J Clin Invest <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33561012 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1172/JCI142677 Languages: – Code: eng Text: English Titles: – TitleFull: Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Burston HE – PersonEntity: Name: NameFull: Kent OA – PersonEntity: Name: NameFull: Communal L – PersonEntity: Name: NameFull: Udaskin ML – PersonEntity: Name: NameFull: Sun RX – PersonEntity: Name: NameFull: Brown KR – PersonEntity: Name: NameFull: Jung E – PersonEntity: Name: NameFull: Francis KE – PersonEntity: Name: NameFull: La Rose J – PersonEntity: Name: NameFull: Lowitz J – PersonEntity: Name: NameFull: Drapkin R – PersonEntity: Name: NameFull: Mes-Masson AM – PersonEntity: Name: NameFull: Rottapel R IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2021 Apr 01 Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1558-8238 Numbering: – Type: volume Value: 131 – Type: issue Value: 7 Titles: – TitleFull: The Journal of clinical investigation Type: main |
| ResultId | 1 |
